Find an expert

Prof David Ascher is currently an NHMRC Investigator and Director of the Biotechnology Program at the University of Queensland. He is also Head of Computational Biology and Clinical Informatics at the Baker Institute.

David’s research focus is in modelling biological data to gain insight into fundamental biological processes. One of his primary research interests has been developing tools to unravel the link between genotype and phenotype, using computational and experimental approaches to understand the effects of mutations on protein structure and function. His group has developed a platform of over 40 widely used programs for assessing the molecular consequences of coding variants (>7 million hits/year).

Working with clinical collaborators in Australia, Brazil and UK, these methods have been translated into the clinic to guide the diagnosis, management and treatment of a number of hereditary diseases, rare cancers and drug resistant infections.

David has a B.Biotech from the University of Adelaide, majoring in Biochemistry, Biotechnology and Pharmacology and Toxicology; and a B.Sci(Hon) from the University of Queensland, majoring in Biochemistry, where he worked with Luke Guddat and Ron Duggleby on the structural and functional characterization of enzymes in the branched-chain amino acid biosynthetic pathway. David then went to St Vincent’s Institute of Medical Research to undertake a PhD at the University of Melbourne in Biochemistry. There he worked under the supervision of Michael Parker using computational, biochemical and structural tools to develop small molecules drugs to improve memory.

In 2013 David went to the University of Cambridge to work with Sir Tom Blundell on using fragment based drug development techniques to target protein-protein interactions; and subsequently on the structural characterisation of proteins involved in non-homologous DNA repair. He returned to Cambridge in 2014 to establish a research platform to characterise the molecular effects of mutations on protein structure and function- using this information to gain insight into the link between genetic changes and phenotypes. He was subsequently recruited as a lab head in the Department of Biochemistry and Molecular Biology at the University of Melbourne in 2016, before joining the Baker Institute in 2019 and the University of Queensland in 2021.

He is an Associate Editor of PBMB and Fronteirs in Bioinformatics, and holds honorary positions at Bio21 Institute, Cambridge University, FIOCRUZ, and the Tuscany University Network.

Dr. Liviu-Gabriel Bodea is a Reserach Fellow at the School of Medical Sciences, Faculty of Medicine. He is also affiliated with the Clem Jones Centre in Ageing Dementia Reserach, Queensland Brain Institute, and a former Mid-Career Fellow of Dementia Australia Research Foundation.

Liviu was awarded his Dr.rer.nat. (PhD) title from the University of Bonn, Germany (2014), working in the group of Prof. Harald Neumann, an expert in microglial physiology who identified for the first time a role for the microglial receptor TREM2 (JEM 2005). Liviu then relocated to Australia as the Peter Hilton Early Career Fellow in Ageing Dementia Research (2014-2019) to conduct work together with Prof. Jürgen Götz, a world-renowned leader in Alzheimer's disease reserach. In 2024, Liviu obtained independent NHMRC founding and moved his work in the laboratory of A/Prof Karin Borges at the School of Biomedical Sciences, where he gains deeper insights into proteostais-induces alterations of cellular metabolism.

Liviu is a brain immune cell biologist focusing on the functional crosstalk between microglia, the main resident immune cells of the brain parenchyma, and the surrounding cell types, both in health and disease. He has significant experience in generating and analysing both in vivo and in vitro models (from stable cell lines and primary cultures to novel genetically modified mice) in combination with various biochemical and molecular techniques, ranging from high-resolution microscopy to de novo proteome pathway analysis and generating novel mouse model through CRISPR gene editing.

Liviu has extensive experience in guiding both undergraduate and postgraduate students into the wonders of scientific research :)

Complete List of Published Work: PubMed Bibliography

Funding and Awards

2024-2027 NHMRC Ideas Grant #2030460 (sole CI, salary and research)

2022-2024 Dementia Australia Research Foundation Mid-Carrier Research Fellowship (salary and research)

2022 The University of Queensland Research Stimulus Fellowship (salary)

2019 Emergency Services Queensland Philanthropic Support (research)

2018-2021 NHMRC Project Grant #1147569 (CIB, salary and research)

2014-2019 Peter Hilton Early Career Research Fellowship in Ageing Dement (salary)

Research Impact, Leadership and Professional Activities

Dr. Bodea attracted >3400 citations (h-index 15 @Google Scholar), including 6 articles with >100 citations (Google Scholar) and 3 Highly Cited Publications (Web of Science). In 2021, Expertscape recognised Dr. Bodea as one of the top-rated researchers in the field of tauopathy, placing him in the top 0.8% of >142k published authors worldwide on tauopathies between 2012 and 2021. His work was cited in 18 patents (5 granted).

Dr. Bodea's work on the microglial TYROBP in late-onset AD (Cell 2013, co-first author, former Highly Cited Publication @Web of Science) represents a milestone in the field, with >1700 citations (Google Scholar). He also revealed the complement-induced neurodegeneration of dopaminergic neurons following peripheral immune stimulation (JNeurosci 2014, first author). More recently, he coordinated studies that centred on the effect of Tau protein (molecule relevant for Alzheimer's disease) on protein synthesis (EMBO J 2019 and Acta Neuropathologica Communications 2021), the use of artificial amino acids and de novo proteome analysis for the investigation of memory (eLife 2020) and microglial physiology (STARProtocols 2023), and the role of neuronal PTEN enzyme in synaptic engulfment by microglia (Acta Neuropathologica 2020). He published authoritative reviews in the Journal of Neurochemistry (2017), Nature Reviews Neurology (2018), Nature Reviews Neuroscience (2018), and Brain Research Bulletin (2021).

Dr. Bodea acts as a grant reviewer for MS Research Australia (since 2019), Alzheimer’s Australia Dementia Research Foundation (since 2016) and NHMRC (since 2021). He was the Lead Guest Editor for a Special Research Topic in Frontiers in Cellular Neuroscience (2023), is a member of the Reviewer Board for Frontiers in Cellular Neuroscience and was a member of the Reviewer Board for the International Journal of Environmental Research and Public Health, Mental Health section. He is an ad-hoc reviewer for various top-tier publications, ranging from Science to Trends in Cell Biology.

Dr. Bodea has mentored and supervised the daily activity of PhD students (2 completed, 1 current), Honours students (4 completed, all awarded First Class distinctions), 2 research assistants, and >10 undergraduate students. His PhD students successfully received various awards (e.g., the Alistair Rushworth Fellowship, Merk-QBI Best Student Publication Award, Best Oral Presentation Award). Both his completed PhD students continue with academic careers: Dr. Joey Benetatos, following a successful post-doctoral training in the Fraenkel Lab (MIT, USA), is currently pursuing his second post-doctoral position in the Prof. Loren Looger group (UCSD, USA), and Dr. Harrison T Evans is holding an Alzheimer's Association Postdoctoral Fellowship and is the Leon Levy Fellow in the Prof. Eric Klann lab (NYU, USA).

Dr Andrew Brooks is the Group Leader of the Cytokine Receptor Signalling Group at the University of Queensland Diamantina Institute (UQ DI) within the Translational Research Institute. Andrew completed his Honours research on Flaviviruses in 1996 at the Department of Microbiology and Immunology at James Cook University and then moved to the Department of Biochemistry to study Dengue Virus where he completed his PhD in 2002. He then moved to St Jude Children’s Research Hospital in Memphis, TN, USA where he researched the role of Epstein-Barr Virus in B-cell lymphomagenesis. He then joined the research group headed by Prof Michael Waters at the Institute for Molecular Bioscience, UQ in 2006 and subsequently began his independent research group at UQ DI in 2014. Andrew’s research interests are in cytokine receptors, cell signalling, oncogenesis, and immunology. His current research focus is on the molecular mechanisms of class I cytokine receptor activation including the growth hormone receptor (GHR), thrombopoietin receptor (TpoR/MPL), IL-7 receptor, and IL-6 receptor (IL-6R). In addition, he is investigating the regulation of inflammation by HLA-G. His research has led to publications in journals including Science, Blood, Hepatology, Oncogene, Nature Cell Biology, and PNAS. He has been the secured of over $12 million in research and commercialisation funding from sources including NHMRC, ARC, Innovation Connections, and Merck. He has a number of national and international collaborations, a scientific founder of a start-up company, and is an Editorial Board member for the Journal Cancers and Human Cell. He was previously a committee member of Australian Early-Mid Career Researchers Forum (AEMCRF) launched by the Australian Academy of Science.

Dr Fernanda Cardoso is a Brazil-born Australian researcher interested in venom peptide-based biodiscovery and therapeutics development. Cardoso was awarded an MSc in Molecular Pharmacology and a PhD with an emphasis in Biochemistry and Immunology and is part of the Institute for Molecular Bioscience, where she develops novel therapies for complex neurological diseases. Cardoso has interdisciplinary training in the fields of neuropharmacology, medicinal chemistry and chemical biology and a strong background in drug discovery, which provides the skills to identify naturally occurring or synthetic bioactive molecules and to study their effects in human physiology with applications in neurologic disorders such as chronic pain, irritable bowel syndrome (IBS), and motor neuron disease (MND). Please see Dr Cardoso’s Grants and Publications list for more details.

Before joining the University of Queensland, Dr Cardoso was part of the Queensland Institute for Medical Research, holding a prestigious CAPES Postdoctoral Fellowship. During this period, Cardoso developed unique high-throughput screen platforms for discovering protein and peptide targets of novel therapies to combat infectious diseases and novel helminth-derived bioactives with anti-inflammatory properties. Please see Dr Cardoso’s Publications list for more details.

Dr Cardoso is currently part of the Centre for Drug Discovery and manages several industry and academic projects studying ion channel modulators derived from natural repertoires, particularly venoms, and developing novel, effective drugs to treat neurological disorders.

David is a Consultant Paediatrician, Metabolic Physician, Clinical Geneticist and clinician researcher. His area of expertise is the diagnosis and management of children with rare diseases. David is involved in multiple ongoing research projects aimed at novel disease discovery, improved diagnostic testing and treatments for children with inherited genetic disorders. He is director of a national clinic for Ataxia Telangiectasia brashat.org.au and has recently been awarded a $2.5 million NHMRC research grant for a phase 2/3 trial for treatment of this disorder.

Paul Dennis leads an exciting research group that applies cutting-edge technologies to understand the roles of microorganisms and their responses to environmental change.

He is also a passionate educator and public speaker who advocates for the importance of biological diversity and evidence-based environmental awareness. He has talked about his research on ABC Radio and a range of other media outlets.

His teaching covers aspects of ecology, microbiology, plant and soil science, and climatology. He considers these topics to be of fundamental importance for the development of more sustainable societies and takes pride in helping others to obtain the knowledge and skills they need to build a better future.

Paul's research has taken him to Antarctica, the Amazon Rainforest, high mountains and oceans. The approaches used in his lab draw on a wide range of expertise in molecular biology, ecology, statistics, computer science, advanced imaging and soil science. He applies these skills to a wide-range of topics and systems including plant-microbe interactions, Antarctic marine and terrestrial ecology, biogeography, pollution and human health.

Genetics of mental health (new research)

We are using the genetic model organism, C. elegans, do investigate the genetic basis of both normal and disordered behaviour. Our current interests are identifying the genes responsible for anxiety and depression as well as the genes for eating disoders and addiction. Using C. elegans as a model organism will also allow us to study gene function as it relates to behaviour.

Molecular mechanisms of phosphine resistance (other research)

Genetic mapping of oxidative stress resistance genes. The fumigant phosphine disrupts oxidative metabolism, resulting in the production of reactive oxygen intermediates. This causes the premature ageing and death of targeted pests. Insect pests of stored grain in Australia now exhibit resistance to phosphine at levels more than 200 times the normal lethal dose.

We have genetically mappedf and identified the genes responsible for phosphine resistance in tall major insect pests of stored grain. We are using a systems biology approach in the model organism C. elegans to understand the molecular basis of phosphine action. Our genetic studies have recently shown that resistance to phosphine is associated with an extension of lifespan

Dr. Richard Gordon leads a multi-disciplinary, industry-partnered research program in Translational Neuroscience which integrates immunology, drug development, pharmacology, metabolomics and microbial metagenomics. His group aims to understand and therapeutically target key pathological mechanisms which drive the onset and progression of neurodegenerative disorders such as Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Their work combines target validation studies in human patients with mechanistic insights from disease models to develop and test novel therapeutic strategies that can be translated towards clinical trials.

Key research themes within this program include:

• Understanding how chronic immune and inflammasome activation contribute to neurodegeneration in the CNS
• The role of gut dysbiosis and gastrointestinal dysfunction in Parkinson’s disease pathophysiology
• Therapeutic targeting of the gut-brain axis for neuroprotection
• Drug discovery, development and repositioning for novel therapeutic targets
• Discovery and validation of clinical biomarkers for PD and ALS
• Clinical trials for disease-modifying therapeutic strategies

Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.

Dr Moyle’s laboratory (www.moylelab.com) uses cutting edge technologies for the synthesis of peptides, protein expression, and protein semi-synthesis to gain insights into the functional roles played by various biochemical pathways, to engineer better protein and peptide therapeutics, and to improve the delivery characteristics of various therapeutic molecules. Specific current areas of interest are detailed below:

1. Subunit Vaccine Development: methods to develop improved vaccines through the combination of recombinant and synthetic approaches to improve immunopotency and tailor immune responses (links to reseach articles on semisynthetic vaccines and peptide vaccines; reviews on vaccine development).
2. Delivery Systems for Nucleic Acid-Based Molecules: multi-component synthetic and recombinant approaches to improve the cellular uptake, and targeted delivery of various oligonucleotide molecules (e.g. siRNA, mRNA, pDNA and CRISPR-Cas9) as an exciting approach to treat or prevent various diseases (links to research articles and reviews).
3. Deciphering the Roles of Post-Translational Modifications: The combination of peptide synthesis and protein semisynthesis to enable the production of large amounts of site-specifically modified species, that can be used to deconvolute the roles played by various post-translational modifications (links to research articles).
4. Peptide/Protein Drugs and Delivery: The study of methods to improve the delivery characteristics of peptide/protein drugs (e.g. poor oral absorption, instability to chemical/enzymatic degradation, and the inability to reach their site/s of action) through chemical engineering approaches.
5. New Approaches for Superbugs: the development of antivirulence approaches, and formulations (e.g. various types of nanoparticles - silver, protein, mesoporous silica), which reduce the ability for microbes to cause disease, and make them more readily treated with antimicrobials, by providing access to synergistic combinations, and reducing the risk of antimicrobial resistance.

Information for Potential Students:

The Moyle lab considers applications from potential students and postdoctoral fellows with an interest in: i) infection control (including subunit vaccine and antimicrobial development); ii) delivery systems for peptide therapeutics; iii) targeted delivery systems; iv) studying the function of posttranslational modifications; and v) delivery systems for nucleic acid-based therapeutics (e.g. siRNA, shRNA, miRNA, mRNA, pDNA and CRISPR-Cas9). If you are interested in working in any of these areas please feel free to contact Dr Moyle (p.moyle@uq.edu.au). Please ensure that you supply an up to date CV; describe why you would like to work in the Moyle lab; provide a listing of publications (preferably with impact factors and citation counts); and indicate what skills you would bring to the lab. Detailed information on our laboratory is available at www.moylelab.com. Preference will be given to students and postdoctoral fellows who have their own funding.

Dr Moyle Biosketch:

Dr Moyle (H-index 30, >2600 citations; >95 publications; 13/8/2024; Google Scholar, ORCID, ResearcherID, and Publons profiles) received a PhD (Dec 2006) and a Bachelor of Pharmacy (Hons I) (Dec 2001) from The University of Queensland (UQ); graduated from the Pharmaceutical Society of Australia pre-registration pharmacist-training course (Nov 2002); and is registered with the Pharmacy Board of Australia. He currently works as an Associate Professor in the UQ School of Pharmacy, where he has been based since 2014.

Dr Moyle works in the fields of medicinal chemistry, chemical biology, and drug formulation, investigating subunit vaccine development, outcomes associated with histone post-translational modifications, and methods to improve the delivery characteristics of oligonucleotide (e.g. siRNA and pDNA), peptide, and protein therapeutics. During his PhD, Dr Moyle developed methods that enabled the synthesis of pure, lipid adjuvanted peptide vaccines, using advanced chemical ligation techniques. In addition, the conjugation of mannose to combined prophylactic/therapeutic human papillomavirus type-16 vaccines, to target dendritic cells, was demonstrated to significantly improve vaccine anti-tumour activity. This work, conducted with leading researchers at the QIMR Berghofer Medical Research Institute (Prof Michael Good & Dr Colleen Olive), established Dr Moyle’s national and international profile in the field of vaccine development, resulting in 11 peer reviewed papers, including top journals in the field (J Med Chem; J Org Chem), as well as 6 review articles and 2 invited book chapters.

Dr Moyle undertook his postdoctoral training in the laboratory of one of the world’s premier chemical biologists, Professor Tom Muir (the Rockefeller University, NY, USA; now at Princeton University, NJ, USA). During this time he developed an extensive knowledge of techniques for protein expression, bioconjugation, bioassays, and proteomics, which represent an essential skill set required for this proposal. As part of this work, Dr Moyle developed novel synthetic routes to generate site-specific ADP-ribose conjugated peptides and proteins. This research was hailed as a major breakthrough in the field, leading to several collaborations, and an exemplary publication in the prestigious chemistry journal JACS. This vast body of work identified the enzyme (PARP10) responsible for mono-ADP-ribosylation of histone H2B, and demonstrated interactions between this modification and several proteins, including BAL, which is associated with B cell lymphomas. In addition, a number of robust chemical methods were developed to enable the synthesis of a complete library of methyl-arginine containing histones, which were incorporated into synthetic chemically-defined chromatin to investigate the site-specific effects of arginine methylation on histone acetylation. This work led to a collaboration with colleagues at Rockefeller to investigate the effects of histone arginine methylation on transcription.

Teaching:

Dr Moyle teaches into the following subjects in the UQ School of Pharmacy.

• PHRM3011 (Quality Use of Medicines) - course coordinator
• PHRM4021 (Integrated Pharmaceutical Development)
• PHRM3021 (Dosage Form Design)
• PHRM2040 (Drug Discovery)

Awards:

2016 - Health and Behavioural Sciences (HABS) faculty commendation for Early Career Citations for Outstanding Contributions to Student Learning (ECCOSL)

2015 - ChemMedChem top 10 cited article of 2013 (link)

2014 - Highest ranked NHMRC development grant (2013; APP1074899)

2013 - Institute for Molecular Biology (IMB) Division of Chemistry and Structural Biology Prize

Associate Professor Muttenthaler is a medicinal chemist working at the interface of chemistry and biology with a strong passion for translational research. His research focuses on neuropeptides and the exploration of Nature's biodiversity to develop molecular tools, diagnostics, and therapeutics. His background in drug discovery and development, as well as his interdisciplinary training in the fields of chemistry, molecular biology and pharmacology, assist him in the characterisation of these highly potent and selective compounds and allow him to study their interactions with human physiology for medical innovations in pain, cancer, gut disorders and neurodegenerative diseases.

I am Professor, NHMRC Investigator Fellow (EL2) and group leader (Exosome Biology Laboratory) at UQ Centre for Clinical Research. I am nationally and internationally (>20 invitations to international meetings in the last 5 years) acknowledged key opinion leader on Extracellular Vesicle (rated 3th worldwide (Top 0.015%) and 1st in Australia in expertise for “Extracellular Vesicles and Exosomes” on Expertscape) and biomarker discovery (140 publications, and >8000 citations in the last 7 year). I have made a major conceptual contribution to EV biology with diagnostic and therapeutic implications. In the last 8 years, my primary research and commercialisation activities have focused on the identification and validation of biomarkers, and development of In Vitro Multivariate Index Assays for clinically relevant complications (including ovarian cancers, and obstetrical syndromes) and their translation into clinical applications. In Academia, I have pursued these objectives through the development and leadership of clinical translation research teams and facilities, both in Australia and overseas. For example, I had a leadership role in established the Centre for Clinical Diagnostics (CCD). Within the UQCCR, I established an exosome research team to evaluate the clinical utility of extracellular vesicles as liquid biopsies, IVDs and therapeutics. Much of our effort in this field of endeavour has involved optimising isolation methods for extracellular vesicles and their analytical analysis - including the use of protein solution array (e.g. Luminex), mass spectrometry profiling (using MS/MS SWATH) and more recently miRNA analysis.

Dr. Alex Smith is a Research Fellow at UQ's School of Chemical Engineering. His interests are in understanding structure: function relationships between complex carbohydrates (such as heparan sulphate) and proteins, and how these interactions can inform the development of glycotherapeutic agents to treat a wide variety of injuries and diseases.

Dr. Susannah Tye joined the Queensland Brain Institute in 2017 and has established a research program within the Asia Pacific Centre for Neuromodulation (QLD, Australia). Before returning to Australia, Dr. Tye directed the Translational Neuroscience Laboratory at the Mayo Clinic (2012-2017). While there she led efforts to develop brain stimulation devices (for rodents and humans) that can quantify neural activity and neurotransmitter dynamics in the living brain. This body of work now forms the basis of the neuropsychiatric arm of the Mayo Clinic’s Deep Brain Stimulation Consortium. Her specific research expertise are in utilising voltammetric (electrochemical) recording techniques to monitor rapid, synaptic neurotransmission in the living brain.

Dr. Tye has over ten years of experience studying neuromodulation in preclinical rodent models and human patients. Her long-term goal is to bridge preclinical and clinical studies to maximise translational impact, specifically in terms of improving patient outcomes for those with severe refractory psychiatric illness. Towards this end, she maintains many international collaborations with both clinical and basic science researchers. Dr. Tye also has a longstanding interest in mentoring young scientists to help them expand their skills in preclinical and basic science research and achieve a successful research career.

My research interests are centred around the structure and function of venom and silk polypeptides produced by arthropods, and their use in biotechnology and medicine. I am a Postdoctoral Fellow in the King laboratory in the Institute for Molecular Bioscience, the University of Queensland, Australia. Currently, I am investigating the composition, function and evolution of neglected insect venoms produced by assassin bugs (Hemiptera: Reduviidae), robber flies (Diptera: Asilidae) and nettle caterpillars (Lepidoptera: Limacodidae).